NNMT: A Drug Target and Biomarker for Cancer and Other Diseases

Target Name: NNMT

NCBI ID: G4837

NNMT

Other Name(s): NNMT_HUMAN | nicotinamide N-methyltransferase | Nicotinamide N-methyltransferase | Nicotinamide N-methyltransferase, transcript variant 1 | NNMT variant 1

NNMT: A Drug Target and Biomarker for Cancer and Other Diseases

NNMT (N-Nitrosyl-Maltoside) is a drug target and biomarker that is derived from the non-coding RNA molecule known as microRNA-181. It is a highly conserved non-coding RNA molecule that is expressed in almost all human tissues and cells . NNMT has been shown to play a critical role in the regulation of gene expression and has been linked to a number of cellular processes, including cell growth, apoptosis, and inflammation. As a result, NNMT has been identified as a potential drug target and biomarker for a variety of diseases.

The discovery and characterization of NNMT began in the late 1990s when researchers identified a highly conserved non-coding RNA molecule in human genomes. Initial studies showed that this molecule was highly expressed in a variety of human tissues and cells, including brain, heart, and cancer cells. The molecule was later named NNMT and was found to be expressed at high levels in almost all human tissues and cells.

Subsequent studies showed that NNMT was involved in the regulation of gene expression and that it played a role in the development and progression of a variety of diseases. For example, NNMT has been shown to be involved in the regulation of cell apoptosis, a process that is regulated by a variety of factors including DNA damage, UV radiation, and chemotherapy.

In addition to its role in apoptosis, NNMT has also been shown to be involved in the regulation of cell growth and differentiation. It has been shown to play a role in the regulation of cell proliferation and in the development of cancer. For example, NNMT has been shown to be involved in the regulation of the growth and differentiation of cancer cells and has been linked to the development of a variety of cancer types, including breast, ovarian, and prostate cancer.

NNMT has also been shown to be involved in the regulation of inflammation and immune response. It has been found to play a role in the regulation of inflammation and has been linked to the development of a variety of inflammatory diseases, including autoimmune diseases and chronic inflammatory disorders.

In addition to its role in inflammation and immune response, NNMT has also been shown to play a role in the regulation of cellular signaling pathways. It has been shown to play a role in the regulation of several signaling pathways, including the TGF-β pathway , the PI3K/Akt pathway, and the NF-kappa-B pathway.

The potential clinical applications of NNMT are vast and varied. As a drug target, NNMT has the potential to be used to treat a variety of diseases, including cancer, autoimmune diseases, and chronic inflammatory disorders. It is also a potential biomarker for a variety of diseases, including cancer and autoimmune diseases.

In addition to its potential clinical applications, NNMT also has the potential to be used as a research tool for the study of gene regulation and disease. The conservation of NNMT across species makes it a valuable resource for the study of the mechanisms of gene regulation and disease.

Overall, NNMT is a drug target and biomarker that has the potential to revolutionize the field of genetics and molecular biology. Further research is needed to fully understand the mechanisms of NNMT's role in disease and to develop effective treatments.

Protein Name: Nicotinamide N-methyltransferase

Functions: Catalyzes the N-methylation of nicotinamide using the universal methyl donor S-adenosyl-L-methionine to form N1-methylnicotinamide and S-adenosyl-L-homocysteine, a predominant nicotinamide/vitamin B3 clearance pathway (PubMed:8182091, PubMed:21823666, PubMed:23455543). Plays a central role in regulating cellular methylation potential, by consuming S-adenosyl-L-methionine and limiting its availability for other methyltransferases. Actively mediates genome-wide epigenetic and transcriptional changes through hypomethylation of repressive chromatin marks, such as H3K27me3 (PubMed:26571212, PubMed:23455543, PubMed:31043742). In a developmental context, contributes to low levels of the repressive histone marks that characterize pluripotent embryonic stem cell pre-implantation state (PubMed:26571212). Acts as a metabolic regulator primarily on white adipose tissue energy expenditure as well as hepatic gluconeogenesis and cholesterol biosynthesis. In white adipocytes, regulates polyamine flux by consuming S-adenosyl-L-methionine which provides for propylamine group in polyamine biosynthesis, whereas by consuming nicotinamide controls NAD(+) levels through the salvage pathway (By similarity). Via its product N1-methylnicotinamide regulates protein acetylation in hepatocytes, by repressing the ubiquitination and increasing the stability of SIRT1 deacetylase (By similarity). Can also N-methylate other pyridines structurally related to nicotinamide and play a role in xenobiotic detoxification (PubMed:30044909)

The "NNMT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NNMT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets